{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:32:46Z","timestamp":1755599566382,"version":"3.41.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","award":["9549"],"award-info":[{"award-number":["9549"]}],"id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["71033"],"award-info":[{"award-number":["71033"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bbrep.2025.102045","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T08:36:06Z","timestamp":1747038966000},"page":"102045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Effects of ibrutinib and venetoclax on the expression of immune checkpoint molecules in leukemic blasts of patients with acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"42","author":[{"given":"Armin","family":"Dozandeh-Jouybari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Mousavi-Mirkalaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8813-6046","authenticated-orcid":false,"given":"Saeid","family":"Taghiloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Karami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Naderisorki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Zaboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Eslami-Jouybari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohid","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3816-8792","authenticated-orcid":false,"given":"Hossein","family":"Asgarian-Omran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bbrep.2025.102045_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.bbrep.2025.102045_bib2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102045_bib3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cncr.28531","article-title":"Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia","volume":"120","author":"Lim","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102045_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/aje\/kwaa215","article-title":"Trends in acute lymphoblastic leukemia incidence in the United States by race\/ethnicity from 2000 to 2016","volume":"190","author":"Feng","year":"2021","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102045_bib5","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"13","key":"10.1016\/j.bbrep.2025.102045_bib6","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3390\/cancers15133346","article-title":"Acute lymphoblastic leukemia immunotherapy treatment: now, next, and beyond","volume":"15","author":"Aureli","year":"2023","journal-title":"Cancers"},{"issue":"10230","key":"10.1016\/j.bbrep.2025.102045_bib7","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102045_bib8","first-page":"178","article-title":"The effects of PI3K\/Akt\/mTOR signaling pathway inhibitors on the expression of immune checkpoint ligands in acute myeloid leukemia cell line","volume":"21","author":"Taghiloo","year":"2022","journal-title":"Iran. J. Allergy Asthma Immunol."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102045_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/jpm11080715","article-title":"Targeted therapy in acute lymphoblastic leukaemia","volume":"11","author":"Salvaris","year":"2021","journal-title":"J. Personalized Med."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102045_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102045_bib11","first-page":"39","article-title":"Small molecule inhibitors as emerging cancer therapeutics","volume":"1","author":"Lavanya","year":"2014","journal-title":"Integr. Cancer Sci. Ther."},{"issue":"24","key":"10.1016\/j.bbrep.2025.102045_bib12","first-page":"3688","article-title":"Rationale for targeting the pre\u2013B-cell receptor signaling pathway in acute lymphoblastic leukemia","volume":"125","author":"M\u00fcschen","year":"2015","journal-title":"Blood,J. Am. Soc. Hematol."},{"issue":"9","key":"10.1016\/j.bbrep.2025.102045_bib13","first-page":"1155","article-title":"Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK","volume":"129","author":"Kim","year":"2017","journal-title":"Blood,J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102045_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3390\/cancers14010150","article-title":"Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"14","author":"Gibson","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbrep.2025.102045_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.737340","article-title":"Mechanisms of immunosuppressive tumor evasion: focus on acute lymphoblastic leukemia","volume":"12","author":"Jim\u00e9nez-Morales","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102045_bib16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41467-022-28839-y","article-title":"Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrep.2025.102045_bib17","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1182\/blood-2023-178240","article-title":"Clinical significance of serum CD155 levels in acute lymphoblastic leukemia patients","volume":"142","author":"Azzazi","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102045_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/diagnostics13020325","article-title":"Prognostic role of CD200 in acute lymphoblastic leukemia patients","volume":"13","author":"Khalil","year":"2023","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102045_bib19","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102045_bib20","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3390\/cancers13071536","article-title":"Mechanisms of immune evasion in acute lymphoblastic leukemia","volume":"13","author":"Pastorczak","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbrep.2025.102045_bib21","doi-asserted-by":"crossref","first-page":"13357","DOI":"10.2147\/OTT.S281519","article-title":"BCL-2 inhibitor venetoclax induces autophagy-associated cell death, cell cycle arrest, and apoptosis in human breast cancer cells","author":"Alhoshani","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.bbrep.2025.102045_bib22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fphar.2019.00697","article-title":"Efficacy and safety of Bcl-2 inhibitor venetoclax in hematological malignancy: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Li","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102045_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89904","article-title":"Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib","volume":"2","author":"Burger","year":"2017","journal-title":"JCI insight"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102045_bib24","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/biomedicines12051012","article-title":"Ibrutinib modulates proliferation, migration, mitochondrial homeostasis, and apoptosis in melanoma cells","volume":"12","author":"Lins","year":"2024","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.bbrep.2025.102045_bib25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1155","article-title":"Calcium signalling: dynamics, homeostasis and remodelling","volume":"4","author":"Berridge","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6703","key":"10.1016\/j.bbrep.2025.102045_bib26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/27094","article-title":"Calcium-a life and death signal","volume":"395","author":"Berridge","year":"1998","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102045_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41420-018-0039-4","article-title":"Bcl-2 regulates store-operated Ca2+ entry to modulate ER stress-induced apoptosis","volume":"4","author":"Chiu","year":"2018","journal-title":"Cell Death Discov."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102045_bib28","first-page":"294","article-title":"Ibrutinib improves the development of acute lymphoblastic leukemia by activating endoplasmic reticulum stress-induced cell death","volume":"73","author":"Li","year":"2018","journal-title":"Die Pharmazie-An Int. J. Pharmaceut. Sci."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102045_bib29","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.3390\/ijms25084368","article-title":"Mechanism of decision making between autophagy and apoptosis induction upon endoplasmic reticulum stress","volume":"25","author":"Kapuy","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrep.2025.102045_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00204-014-1448-7","article-title":"The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update","volume":"89","author":"Siddiqui","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bbrep.2025.102045_bib31","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1182\/blood-2023-178766","article-title":"Phase I study of response-adapted treatment with venetoclax, obinutuzumab, and magrolimab (Venom) in relapsed and refractory indolent B-cell Malignancies","volume":"142","author":"Lakhotia","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.bbrep.2025.102045_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2022-170188","article-title":"Phase I\/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"140","author":"Daver","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.bbrep.2025.102045_bib33","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1182\/blood-2022-157606","article-title":"Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with Azacitidine and Venetoclax in PATIENTS with Acute Myeloid Leukemia (ASPEN-05): results from phase 1a dose escalation part","volume":"140","author":"Garcia-Manero","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbrep.2025.102045_bib34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11239-019-01894-x","article-title":"Vincristine induces procoagulant activity of the human lymphoblastic leukemia cell line Jurkat through the release of extracellular vesicles","volume":"48","author":"Pluchart","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102045_bib35","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/hon.3009","article-title":"Anti\u2010CD47 immunotherapy in combination with BCL\u20102 inhibitor to enhance anti\u2010tumor activity in B\u2010cell lymphoma","volume":"40","author":"Li","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.bbrep.2025.102045_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107531","article-title":"Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia","author":"Jestrabek","year":"2024","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102045_bib37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2334\/josnusd.53.169","article-title":"CD47 regulates the TGF-\u03b2 signaling pathway in osteoblasts and is distributed in Meckel's cartilage","volume":"53","author":"Shimada","year":"2011","journal-title":"J. Oral Sci."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102045_bib38","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/JCMRP.JCMRP_159_19","article-title":"Expression of programmed death ligand-1 in B-cell acute lymphoblastic leukemia","volume":"5","author":"Gaber","year":"2020","journal-title":"J. Curr. Med. Res. Pract."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102045_bib39","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.pathol.2021.02.013","article-title":"Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis","volume":"53","author":"M\u00e4kinen","year":"2021","journal-title":"Pathology"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102045_bib40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1309\/AJCPO4U4VYAAOTEL","article-title":"BCL6 expression correlates with the t (1; 19) translocation in B-lymphoblastic leukemia","volume":"143","author":"Deucher","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102045_bib41","doi-asserted-by":"crossref","first-page":"704","DOI":"10.4049\/jimmunol.1800876","article-title":"BCL6-mediated silencing of PD-1 ligands in germinal center B cells maintains follicular T cell population","volume":"202","author":"Peng","year":"2019","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102045_bib42","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrep.2025.102045_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111211","article-title":"Combination therapy of acute myeloid leukemia by dual PI3K\/mTOR inhibitor BEZ235 and TLR-7\/8 agonist R848 in murine model","volume":"125","author":"Taghiloo","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102045_bib44","article-title":"Expression modulation of immune checkpoint molecules by ibrutinib and everolimus through STAT3 in MCF-7 breast cancer cells","volume":"21","author":"Soltanshahi","year":"2022","journal-title":"Iran. J. Pharm. Res. (IJPR): IJPR"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102045_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102045_bib46","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3324\/haematol.2019.238154","article-title":"Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in E-TCL1 mice","volume":"106","author":"Hanna","year":"2020","journal-title":"Haematologica"}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825001323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825001323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:21:56Z","timestamp":1749036116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580825001323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":46,"alternative-id":["S2405580825001323"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102045","relation":{},"ISSN":["2405-5808"],"issn-type":[{"type":"print","value":"2405-5808"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of ibrutinib and venetoclax on the expression of immune checkpoint molecules in leukemic blasts of patients with acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102045"}}